-
Tesla 'Bringing A Machine Gun To A Knife Fight,' Canaccord Genuity Analyst Says
Monday, April 12, 2021 - 3:32pm | 333Read More...Canaccord Genuity upgraded Tesla Inc (NASDAQ: TSLA) for three reasons, analyst Jed Dorsheimer said on CNBC's "Squawk On The Street" Monday. The analyst said he expects delivery numbers to lead to greater profitability because of the transition from low-...
-
Why This Tesla Analyst Is Turning Bullish
Monday, April 12, 2021 - 11:26am | 284Read More...Although Tesla Inc’s (NASDAQ: TSLA) stock valuation is rich, the company seems to have crossed the electric vehicle chasm and is now aggressively foraying into storage, according to Canaccord Genuity. The Tesla Analyst: Jed Dorsheimer upgraded the rating for Tesla's stock from Hold...
-
DraftKings Analysts Cheer Strong Q4, Sports Betting Growth And SBTech Integration
Monday, March 1, 2021 - 7:35pm | 611Read More...DraftKings Inc (NASDAQ: DKNG) received several price target raises after the strong fourth quarter reported on Friday. The DraftKings Analysts: Canaccord Genuity analyst Michael Graham reiterates a Buy rating and raises the price target from $65 to $80. Bank of America analyst Shaun C. Kelley...
-
Here's What Slack Analysts Say Investors Should Do Now
Wednesday, December 2, 2020 - 12:51pm | 452Read More...Slack Technologies Inc (NYSE: WORK) shares have rallied 45.5% in just over a week following the initial reports of a buyout by salesforce.com, inc. (NYSE: CRM). On Tuesday, Salesforce confirmed a buyout deal priced at roughly $44.07 per share as of Wednesday morning’s prices. Slack also...
-
Spirit AeroSystems Analyst Turns Bullish, Sees 'Broader Aerospace Recovery'
Friday, November 20, 2020 - 12:07pm | 258Read More...The FAA's ungrounding of the 737 Max and recent positive coronavirus vaccine news bode well for Spirit AeroSystems Holdings, Inc. (NYSE: SPR), according to Canaccord Genuity. The Spirit AeroSystems Analyst: Ken Herbert upgraded Spirit AeroSystems from Hold to Buy and raised the price...
-
Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021
Thursday, October 8, 2020 - 3:21pm | 562Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail. The experimental drug, named REGN-COV2, was in news last week after it was administered to President...
-
Intuitive Surgical's Outlook 'Has Never Been Stronger,' Analyst Says After Q2 Report
Wednesday, July 22, 2020 - 6:10pm | 318Read More...Intuitive Surgical, Inc.'s (NASDAQ: ISRG) second-quarter report Tuesday was “surprisingly positive,” according to Canaccord Genuity. The Intuitive Analyst: Cecilia Furlong maintained a Buy rating on Intuitive and raised the price target from $562 to $725. The Intuitive Thesis:...
-
Apple Analyst Boosts Price Target By 43% Ahead Of 5G iPhone Ramp
Thursday, July 16, 2020 - 9:56am | 345Read More...Apple Inc. (NASDAQ: AAPL) is well-positioned for improving results in the back half of 2020 and in 2021 as the 5G cycle powers up, according to Canaccord Genuity. The Apple Analyst: Michael Walkley maintained a Buy rating on Apple and raised the price target from $310 to $444. The Apple...
-
Canaccord's Graham Defends Bullish DraftKings Rating On 'Fast Money'
Thursday, July 9, 2020 - 11:16am | 423Read More...The bullish case for online sports betting company Draftkings Inc (NASDAQ: DKNG) remains unchanged at a time when the resumption of professional sports is in question, according to Canaccord Genuity's Michael Graham. DraftKings As A Long-Term Play: Sports fans across the U.S. never had access...
-
Psychedelics Co. Champignon Announces New CEO, $10M In Funding And M&A Deal
Wednesday, May 13, 2020 - 7:30am | 621Read More...Psychedelic-focused health company Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) recently made a string of announcements. The company confirmed Dr. Roger McIntyre as its new CEO, a private placement raise of $10 million and the acquisition of a California-based ketamine treatment centre which marks...
-
Tilray Shares Plunge On The Heels Of $90.4M Equity Offering
Friday, March 13, 2020 - 2:13pm | 251Read More...Tilray Inc. (NASDAQ: TLRY) announced Friday that it has priced a $90.4-million equity offering. The Nanaimo, Canada-based company is offering 7.25 million Class 2 shares and, in place of Class 2 shares, pre-funded warrants to buy 11.75 million Class 2 shares and accompanying...
-
Boeing Analyst Slashes Price Target, Says Plane Manufacturer's Outlook Just Got A Lot 'Murkier'
Thursday, March 12, 2020 - 11:39am | 356Read More...The impact of the coronavirus on the airline industry has created a much gloomier outlook for already-struggling Boeing Co (NYSE: BA), according to Canaccord Genuity. The Boeing Analyst Ken Herbert maintained a Hold rating on Boeing and reduced the price target from $340 to $225. The...
-
Canaccord Pumps The Brakes On Tesla Following Stock's Huge Run
Wednesday, February 5, 2020 - 12:50pm | 327Read More...After the massive spike in Tesla Inc’s (NASDAQ: TSLA) stock so far this year, it’s time for investors “to lock in profits,” according to Canaccord Genuity. The Tesla Analyst Jed Dorsheimer downgraded Tesla from Buy to Hold with an unchanged $750 price target. The Tesla...
-
'Leader Of The EV Revolution': 5 Analysts Weigh In On Tesla's Q4 Beat
Thursday, January 30, 2020 - 1:25pm | 802Read More...Tesla Inc (NASDAQ: TSLA) exceeded fourth-quarter earnings expectations with a $2.14 adjusted bottom line and $7.38 billion in revenue. Management closed the quarter with $6.3 billion in cash and $1 billion in free cash flow — $1.1 billion better than Morgan Stanley’s $100 million burn...
-
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Monday, January 27, 2020 - 12:18pm | 403Read More...Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat. The Analyst Sumant Kulkarni upgraded Biogen from Hold to Buy and increased the price target from $305 to...
